Literature DB >> 17886162

Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmas.

Muamer Omerovic1, Harald Hampel, Stefan J Teipel, Katharina Buerger.   

Abstract

Alzheimer's disease (AD) is one of the most frequent disorders of the central nervous system characterised by a progressive cognitive decline. The demographic changes of our aging population lead to increased numbers of patients and a need of early diagnosis and treatment of cognitive and behavioural symptoms of AD. Drugs are available for symptomatic treatment of AD. The pharmacological treatment of behavioural disturbances experienced dynamic changes in the last years. In this paper, we present the current state and future perspectives in the treatment of AD. Furthermore, we discuss current difficulties regarding AD treatment by looking for explanations for a still unsatisfying rate of state-of-the-art treatment of AD-patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17886162     DOI: 10.1080/15622970701568412

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  3 in total

1.  Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's Aβ peptide and reduce its cytotoxicity.

Authors:  Jermont Chen; Anne H Armstrong; Angela N Koehler; Michael H Hecht
Journal:  J Am Chem Soc       Date:  2010-11-09       Impact factor: 15.419

Review 2.  Cognitive intervention in Alzheimer disease.

Authors:  Verena Buschert; Arun L W Bokde; Harald Hampel
Journal:  Nat Rev Neurol       Date:  2010-08-17       Impact factor: 42.937

3.  Impact of Mixed Cognitive Intervention Training on Early Onset Dementia.

Authors:  Bo-Ra Jeon; Deok-Ju Kim
Journal:  Osong Public Health Res Perspect       Date:  2021-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.